EDSA News and Press, Edesa Biotech Inc. From 08/29/19

TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8...

Edesa Biotech (NASDAQ: EDSA ): Q2 GAAP EPS of -$0.30. More news on: Edesa Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on its business. During the quarter, Edesa complet...

TORONTO, ON / ACCESSWIRE / July 25, 2019 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, reported today that the company has completed the manufacturing of its lead drug candidate EB01, a novel sPLA2 inhibitor that Edesa is developing as a potential trea...

Edesa Biotech ( EDSA ) is having a good 2019 so far. That's because it received the go-ahead from the FDA to initiate a phase 2b study using its treatment EB01 for patients with chronic contact dermatitis. The stock has made remarkable progress gaining about 592% year to date. It is using ...